🔬 Droplets with steering wheel show chemistry power

Scientists have created unique two-phase droplets that can be controlled like tiny vehicles. Rakesh Narani, working at National Tsing Hua University, engineered these Janus droplets using hydrocarbon and fluorinated liquids. Magnetic iron oxide nanoparticles were placed at the boundary to create visible dividing lines between the two halves. By manipulating an external magnetic field, Narani can actively steer and drive these microscopic droplets. This technology shows potential for future uses in sensing, catalysis, and drug delivery applications.

✨ Holland & Zendaya Smash Box Office Records

Spider-Man: Brand New Day and The Odyssey achieved a massive $430 million weekend in North America. This success featured Tom Holland, Zendaya, and Jon Bernthal across both movies. The combined haul beat the previous record of $402 million set in 2019. Holland plays Telemachus in Nolan’s epic while Zendaya reprises her role in Spider-Man. The films continue their strong run after their July releases. 🚀

📉 Bhai Tera Star Hai flops big time at box office

The film Bhai Tera Star Hai has seen a major rejection from the audience, officially confirmed by the first Monday's performance. Starring Raghav Juyal, the movie was released on July 30th and performed poorly across India. On Day 5, collections dropped to just 6 lakh, totaling an estimated 97 lakh net over five days. This marks a massive 76% crash compared to its opening day of 25 lakh. The movie's total net collection is projected between 1.15-1.25 crore, significantly less than 'Kill'.

🚀 Can SpaceX keep pushing the boundaries?

SpaceX continues its ambitious trajectory in the aerospace sector. The company is known for its innovative rocketry designs and missions. Key metrics include its recent launch cadence and ongoing development projects. This ongoing push tests the limits of current space technology and engineering prowess. Future developments will determine if SpaceX maintains its pioneering momentum. 🚀

🚭 Quitting smoke: the fourth pillar of cancer care

Quitting tobacco is considered the 'fourth pillar' of cancer care, alongside surgery, radiation, and chemo. This vital intervention is often missed by patients across various cancer types in places like the University of Wisconsin-Madison. A 2025 analysis showed those who quit had significantly lower mortality risks compared to smokers. The gap exists due to implementation issues like lack of staff training and funding, not lack of evidence. New standards now require screening and referral within 30 days for newly diagnosed patients. 🚭

❤️ Heart Failure Mortality Dropping in Sweden 🇸🇪

Advanced heart failure mortality rates significantly decreased in Sweden between 2003 and 2022. Researchers studied 5323 patients with AdvHFrEF in Sweden over those two decades. Overall, 1-year all-cause mortality dropped from 46.1 to 32.9 per 100 person-years. CV mortality saw a major decline, but uptake of advanced therapies stayed low even for eligible patients. Future improvements require earlier patient identification and better access to these treatments.

🩺 Cushing Syndrome linked to bad outcomes in tumors

Ectopic Cushing syndrome (ECS) was connected to shorter overall survival and more health issues in patients with neuroendocrine neoplasms. The study involved 264 patients at a global network, comparing those with ECS to those without it. At 8 years, ECS patients had a 55.3% survival rate versus 71.2% for the other group. This suggests Cushing-related complications, not just tumor growth, drive the higher mortality. Early diagnosis and aggressive management of high cortisol are crucial moving forward. 🩺

🤰 GLP-1 use during pregnancy not linked to HDP risk

A meta-analysis found no significant link between GLP-1 RA exposure and increased risk of hypertensive disorders of pregnancy (HDP). Researchers conducted the review across three US retrospective cohort studies between 2014 and 2025. The analysis included 10,880 pregnancies, with 4942 exposed to GLP-1 RAs. The pooled analysis showed an odds ratio of 0.91 with a P value of .70, indicating no statistical association. Further prospective trials are necessary to build clinical strategies for high-risk categories. 🤰

🔬 Gene editing trial ends tragically in Shanghai

A 6-year-old girl died after receiving an experimental gene editing therapy at Xinhua Hospital in Shanghai, China. The treatment, led by neuroscientist Zilong Qiu, targeted a rare CHD3 gene variant in the girl’s brain. The adverse events followed an infusion on March 24, leading to severe toxicity and death one week later. Investigators found preclinical warnings regarding liver and kidney injury were ignored and consent forms omitted the risk of death. This undisclosed fatality highlights major gaps in clinical trial oversight and scientific transparency. 😥

🔬 Stress can flip a crystal's handedness 🤯

Researchers in Germany and the UK found a material whose chirality flips under physical stress, which they named the piezochiral effect. This discovery was made by groups led by Andrea Cavalleri at the Max Planck Institute in Hamburg and Paolo Radaelli at the University of Oxford. In 2025, they demonstrated this using silver gallium sulfide under strain, showing transient changes with terahertz pulses. The material's structure contains balanced alternating chiral regions that pressure can disrupt to create net chirality. This breakthrough could allow for controlling asymmetric catalysis, letting scientists switch between right- and left-handed molecules as needed.

🛡️ Nirsevimab cuts IPD hospitalizations in infants

Nirsevimab immunization was linked to significantly lower odds of hospitalizing for invasive pneumococcal disease (IPD) in infants. This research used data from a nationwide French cohort involving 527,971 children born between February 2023 and January 2024. The study showed a 36% lower odds of hospitalization at 6 months and 34% at 9 months. This indicates nirsevimab could lower the overall burden of IPD beyond existing PCV vaccines. Further monitoring will track the impact of this immunization in real-world settings.